Q3 Loss Widens to $64.6M on $57.1M Non-Cash Warrant Charge; Cash Falls to $22M
AZR has more than doubled off its 52-week low of $1.31.
Summary
Azora's Q3 2026 net loss widened to $64.6M, or $4.52 per share, from $1.8M, or $2.02 per share, a year earlier, but $57.1M of that was a non-cash warrant-liability charge, so the operating loss is far smaller than the headline number. Cash fell to $22.0M from $28.7M at June 30, 2026, a $6.7M quarterly burn, and the company says that funds its current plan excluding warrant proceeds. Up to roughly $32.4M in gross proceeds could come from investors electing to buy milestone warrants, but that funding is not assured. R&D expense rose to $1.8M from $0.5M as preclinical and toxicology work for AT177 ramps. The next hard milestone is the AT177 IND submission and Phase 1a start, both planned for H1 2027.
At the time of this announcement, AZR was trading at $3.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $53.3M. The 52-week trading range was $1.31 to $8.75. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.